| scholarly article | Q13442814 |
| P2093 | author name string | Sunil Manjila | |
| Robert T Geertman | |||
| Maya Madhavan | |||
| Aleka Scoco | |||
| Arshneel Singh Kochar | |||
| Vaijayantee K Belle | |||
| P2860 | cites work | VEGF-Trap: a VEGF blocker with potent antitumor effects | Q24535043 |
| Mechanisms of tumor development and anti-angiogenic therapy in glioblastoma multiforme | Q26999917 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Get a ligand, get a life: integrins, signaling and cell survival | Q28645744 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| Requirement of vascular integrin alpha v beta 3 for angiogenesis | Q29619681 | ||
| Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma | Q30661157 | ||
| Safety of anticoagulation use and bevacizumab in patients with glioma | Q31153632 | ||
| RGDS peptide induces caspase 8 and caspase 9 activation in human endothelial cells | Q33198615 | ||
| Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. | Q33375093 | ||
| Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 | ||
| Phase 2 study of dose-intense temozolomide in recurrent glioblastoma | Q33406808 | ||
| A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). | Q33411920 | ||
| Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma | Q33414998 | ||
| Bevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort | Q33416917 | ||
| Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial | Q33417361 | ||
| A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306) | Q34269566 | ||
| Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches | Q34515465 | ||
| Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme | Q34871632 | ||
| Role of integrins in cell invasion and migration | Q35084782 | ||
| Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study | Q35114460 | ||
| Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma | Q35570248 | ||
| Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study | Q35788615 | ||
| Angiogenesis in gliomas: biology and molecular pathophysiology | Q36359221 | ||
| Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma | Q36755742 | ||
| CCR drug updates: sorafenib and sunitinib in renal cell carcinoma | Q36868114 | ||
| Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation | Q37187715 | ||
| VEGF Trap induces antiglioma effect at different stages of disease | Q37284357 | ||
| Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 | ||
| FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? | Q37333639 | ||
| Targeting integrins in malignant glioma | Q37785812 | ||
| The role of avastin in the management of recurrent glioblastoma | Q37996222 | ||
| Integrin inhibitor cilengitide for the treatment of glioblastoma: a brief overview of current clinical results | Q38051608 | ||
| Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups | Q38237318 | ||
| Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumours in vivo | Q38282838 | ||
| Assessing the activity of cediranib, a VEGFR-2/3 tyrosine kinase inhibitor, against VEGFR-1 and members of the structurally related PDGFR family | Q39569822 | ||
| Effect of the angiogenesis inhibitor Cilengitide (EMD 121974) on glioblastoma growth in nude mice | Q40174682 | ||
| Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours | Q40592751 | ||
| LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice | Q40620827 | ||
| Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. | Q42817299 | ||
| Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist | Q43517798 | ||
| Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders | Q44150789 | ||
| Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ | Q44442888 | ||
| Antiangiogenic effects of a protein kinase Cbeta-selective small molecule | Q45713422 | ||
| Inhibition of alpha(v)beta3 integrin survival signaling enhances antiangiogenic and antitumor effects of radiotherapy | Q46689439 | ||
| Phase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012. | Q46748093 | ||
| Bevacizumab plus irinotecan in recurrent glioblastoma multiforme | Q46942082 | ||
| Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma | Q48264845 | ||
| A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme | Q48344081 | ||
| alpha v-Integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and tenascin | Q48647829 | ||
| Bevacizumab for newly diagnosed glioblastoma | Q48768266 | ||
| Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors | Q48874982 | ||
| Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients | Q49123780 | ||
| Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study. | Q53627483 | ||
| Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study. | Q55461530 | ||
| Assessment of the biological and pharmacological effects of the alpha nu beta3 and alpha nu beta5 integrin receptor antagonist, cilengitide (EMD 121974), in patients with advanced solid tumors | Q80785300 | ||
| Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with promising activity for glioblastoma multiforme | Q81615619 | ||
| Bevacizumab for newly diagnosed glioblastoma | Q87922532 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | glioblastoma | Q282142 |
| angiogenesis inhibitor | Q574834 | ||
| P304 | page(s) | 546-554 | |
| P1433 | published in | Asian journal of neurosurgery | Q26842833 |
| P1476 | title | Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme | |
| P478 | volume | 13 |
| Q98179308 | Tumor Treating Fields in the Management of Patients with Malignant Gliomas | cites work | P2860 |
Search more.